Analyst Price Target is $31.00
▲ +105.57% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Harpoon Therapeutics in the last 3 months. The average price target is $31.00, with a high forecast of $40.00 and a low forecast of $16.00. The average price target represents a 105.57% upside from the last price of $15.08.
Current Consensus is
The current consensus among 9 contributing investment analysts is to buy stock in Harpoon Therapeutics. This Buy consensus rating has held steady for over two years.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.